fda approv xeljanz strengthen inform immunolog franchis
maintain buy rate upgrad tp
estim non-gaap ep forward
earn multipl provid upsid
potenti estim revenu growth
base estim follow factor strong
growth major brand includ ibranc eliqui lyrica ih
xeljanz robust growth biosimilar eh segment
continu uptak inflectra/remsima develop market
europ launch
growth xtandi allianc revenu
partnership astella submit prosper
data fda seek expand label non-
number urologist activ prescrib xtandi continu
grow reach all-tim high
compar zytiga
term expect impact
expect impact remain
rang improv
less
miss revenu estim slightli due continu
product howev strong bottom-lin growth pfe
adjust ep beat estim number
compani name inc tickerpfestock ratingbuyunchangedindustri viewoverweightpositivepric feb week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth except ep crispidea inc march
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
pfizer revenu stood compar
increas y/i
increas reflect favor impact foreign exchang
partli off-set oper declin
net incom quarter compar
net margin exclud tax benefit
quarter compar
ep quarter compar
compar eh
revenu declin oper y/i
compar
oper due februari divestitur
seen consist increas price strong
growth net margin pfe blockbust like ibranc xtandi
eliqui etc gain traction world-wide expect
growth increas maintain buy
rate target price
price-to-earnings show signific volatil around mean due
price chang price-to-earnings fell standard
deviat occas due grow ep
declin stock price prove better year
maintain strong price-to-earnings back constant price
increas due recent decreas price price-to-earnings
revert back mean level
oper margin roa roi roe
ttm basi respect gaap
ep
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date ex-dividend date feb last split factor new per last split date jul inform pfizer inc ch
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement item month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research interest expens incom net operating- unusu expens oper expens total- total oper oper interest incom expens net non-operating- loss sale net- incom incom minor equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli inc march
 short term short term account receiv trade receiv other- total receiv total prepaid expenses- current asset total current property/plant/equip total goodwil intang long term long term asset total account accru note payable/short term current port lt debt/capit current liabil total current long term capit leas obligations- total long term total defer incom minor liabil total redeem prefer stock total- prefer stock non redeem common stock addit paid-in retain earn accumul treasuri stock equiti total total liabil sharehold share out common stock primari issue- total common share actual annual actual quarterli balanc sheet item pfizer inc march
net cash provid oper activ compar increas
reflect time receipt custom payment vendor ordinari cours busi
partial off-set increas benefit plan contribut
net cash use invest activ compar chang
due decreas cash use acquisit fro increas invest
activ includ dividend receiv invest
net cash use financ activ compar increas
primarili due issuanc long-term debt cash dividend paid
cash equival compar
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid inc march
deliv strong quarterli result oper revenu growth
exclud hsp infus system period led strong growth
major brand newly-acquir product includ xtandi saw strong
increas margin doubl digit growth decreas cost well
adjust ep quarter beat estim
pfizer revenu stood compar
increas y/i increas reflect favor impact
foreign exchang partli off-set oper declin
cog increas y/i compar
gross margin quarter compar
 expens quarter decreas y/i compar
si expens quarter increas y/i
compar
amort expens quarter increas y/i
compar increas primarili due
inclus amort expens quarter
deduct quarter compar
increas y/i increas due increas interest
expens decreas royalti incom loss earli retir debt
increas partli off-set lower asset impair charg loss
re-measur
ebit quarter compar
increas y/i ebit increas increas revenu decreas
cost oper margin quarter compar
net incom quarter compar
net margin exclud tax benefit quarter compar
ep quarter compar
stood
compar
increas y/i
quarter increas
y/i
compar
net incom
quarter
compar
net margin
quarter
compar
ep
quarter
compar
total revenu
compar
decreas
cog
compar
si expens
flat y/i
compar
total revenu compar
decreas y/i decreas reflect unfavour impact
result one less sell day intern market
slight oper decreas unfavor impact foreign
exchang
cog compar decreas
y/i decreas primarili due
favor impact sale global oper carri
higher cost sale product
recognit synergi relat cost-reduction/product initi
non-recurring unfavor impact acquir hospira
inventori measur fair valu acquisit date
amort turn relat inventori
favor impact foreign exchang favor off-set
hedg gain
favor chang product mix includ oper declin sip
portfolio favor attribut product lost exclus
partial off-set
inventori loss overhead cost relat period
puerto rico plant oper increment cost date
result recent hurrican puerto rico
si expens flat y/i compar
primarili due
non-recurr allow doubt trade account receiv
result unfavor develop distributor
record
lower advertis promot field forc expens reflect
benefit cost-reduct product initi
lower spend certain product primarili prevnar
 expens
compar
decreas
favor impact sale global oper
lower spend viagra due loss exclus decemb
partli off-set
xeljanz well biosimilar primarili relat launch
increas charit contribut includ charit
contribut pfizer foundat organ provid grant
invest fund support organ social entrepreneur
effort improv healthcar deliveri
 expens compar
decreas y/i decreas due
lower expens due discontinu global clinic
develop program bococizumab non-recurr
associ close-out cost
partli off-set
increas cost associ oncolog program primarili clinic trial
spend mediv asset
lower develop fund credit primarili relat
discontinu global clinic develop program bococizumab
increas cost associ difficil vaccin program
initi phase clinic studi march
expens result may agreement sangamo
develop commerci gene therapi program hemophilia
increas cost associ late stage develop program includ
xtandi talazoparib tanezumab
amort expens compar
increas increas due amort expens
pre-tax associ identifi intang asset
acquir mediv anacor partial off-set asset becam
fulli amort end estim use live favor
impact februari sale
ebit increas y/i compar
increas due higher percent decreas oper expens
decreas revenu oper margin
compar
net incom compar
increas due one time tax benefit relat re-measur
defer tax-liabl ep compar
compar
increas
ebit
y/i compar
oper margin
compar
net incom
compar
gaap ep
compar
manag commerci oper two distinct busi
innov ih pfizer essenti eh
ih revenu increas oper y/i compar
increas driven continu growth key
brand includ ibranc eliqui global addit xtandi revenu
 result septemb acquisit mediv well
lyrica xeljanz primarili
increas partli off-set lower revenu enbrel develop
european market due continu biosimilar competit also viagra
 primarili due wholesal destock advanc anticip
competit gener begin decemb
ih revenu increas oper y/i compar
increas driven continu growth key brand
includ ibranc eliqui global addit xtandi revenu
result septemb acquisit mediv well lyrica
xeljanz primarili
global prevnar revenu declin oper
 prevnar revenu declin primarili due
continu declin revenu adult indic due smaller remain
catch opportun partial off-set increas govern purchas
compar pediatr indic
oper y/i
compar
oper
 prevnar
primarili due
continu declin
revenu adult
indic due
opportun
prevenar revenu
oper
prevenar revenu intern market increas oper
primarili due favor overal impact time increas
volum associ govern purchas certain emerg market
pediatr indic compar year-ago quarter well
inclus prevenar addit nation immun program certain
emerg market adult pediatr indic
cog increas primarili driven increas royalti expens
mostli relat ibranc partial off-set favor chang product mix
si increas y/i primarili driven non-recurr
allow doubt trade account receiv result unfavor
develop distributor record lower spend
certain product primarili prevnar viagra lost
exclus decemb partial off-set addit
invest across sever key product primarili eucrisa ibranc xeljanz
decreas expens y/i primarili reflect
discontinu global clinic develop program bococizumab
partial off-set increas cost associ difficil vaccin
program initi phase clinic studi march oncolog
program primarili clinic trial spend legaci mediv asset
eh revenu declin oper y/i compar
oper due februari
divestitur revenu also neg impact
oper declin peri-lo product primarili due expect declin
pristiq well lyrica develop europ eh revenu also
neg impact oper declin steril inject
sip portfolio primarili due continu legaci hospira
product shortag
declin partial off-set oper growth biosimilar
primarili inflectra develop europ
eh revenu declin oper y/i compar
revenu also neg impact
oper declin peri-lo product primarili due expect declin
pristiq well lyrica develop europ eh revenu also
neg impact oper declin steril inject
sip portfolio primarili due continu legaci hospira
product shortag
decreas
expens y/i
discontinu
global clinic
bococizumab
oper y/i
compar
oper due
februari
divestitur
oper y/i
compar
eh revenu emerg market grew oper fro
primarili driven oper growth legaci establish
product portfolio oper growth sip portfolio exclud
period eh revenu emerg market grew
cog decreas y/i primarili due favor impact
sale higher cost sale eh product net
decreas royalti expens lower volum mainli driven steril
inject pharmaceut sip portfolio primarili due legaci hospira
product shortag favor impact foreign exchang
si expens decreas y/i primarili due favor
impact sale lower advertis promot field forc
expens reflect benefit cost-reduct product initi
well lower expens associ product recent lost market
exclus partial off-set increas spend biosimilar primarili
relat launch inflectra
 expens decreas y/i primarili due decreas
spend biosimilar close-out certain post-market clinic trial
favor impact sale
eh revenu emerg
oper
growth legaci
portfolio
oper growth
sip portfolio
y/i
primarili due
decreas spend
biosimilar close-out
certain post-
favor impact
sale
merck kgaa
announc fda
btd avelumab
combin inlyta
axitinib treatment-
nave patient
announc fda
indic expand
use sutent includ
adjuv treatment
adult patient high
risk recurr renal
product pipelin develop
oper biopharmaceut busi emd serono
canada merck kgaa announc fda grant
breakthrough therapi design btd avelumab combin
inlyta axitinib treatment-nav patient advanc renal cell
btd base preliminari evalu clinic data javelin
renal global phase studi assess safeti efficaci
avelumab combin inlyta treatment treatment-nav
patient advanc rcc btd design acceler develop
review potenti medicin seriou condit preliminari
clinic evid indic therapi may demonstr substanti
improv current avail therapi one clinic
signific endpoint second btd grant avelumab
inlyta approv monotherapi treatment advanc rcc
failur one prior system therapi
novemb merck kgaa announc phase
javelin gastric trial meet primari endpoint superior overal
surviv single-ag avelumab compar physician choic
chemotherapi trial investig avelumab third-lin treatment
unresect recurr metastat gastric gastroesophag junction
therapeut regimen regardless program death
safeti profil avelumab consist observ overal
javelin clinic develop program javelin gastric data
examin effort better understand result also
submit present upcom medic congress outcom
javelin gastric impact current avelumab
sutent sunitinib malat novemb announc fda
approv new indic expand use sutent includ
adjuv treatment adult patient high risk recurr renal cell
product pipelin develop
bosulif bosutinib decemb announc fda
approv supplement new drug applic snda expand
indic bosulif includ adult patient newlydiagnos chronic
cml snda review approv fda prioriti review
acceler approv program base molecular cytogenet
continu approv indic may conting upon verif
confirm clinic benefit on-going long-term follow trial
bosulif first approv septemb treatment
adult patient chronic acceler blast phase ph cml
resist intoler prior therapi
steglatro ertugliflozin steglujan ertugliflozin sitagliptin
segluromet ertugliflozin metformin hydrochlorid decemb
merck known msd outsid canada announc
fda approv steglatro ertugliflozin tablet oral sodium-glucos
cotransport inhibitor adjunct diet exercis improv
glycem control adult type diabet mellitu
sitagliptin tablet adjunct diet exercis improv glycem
control adult type diabet mellitu treatment
ertugliflozin sitagliptin appropri segluromet ertugliflozin
metformin hydrochlorid tablet adjunct diet exercis
improv glycem control adult type diabet mellitu
adequ control regimen contain ertugliflozin metformin
patient alreadi treat ertugliflozin metformin
januari committe medicin product human use
chmp european medicin agenc recommend approv
steglatro steglujan segluromet european commiss
review chmp recommend decis expect
announc fda
snda expand
indic bosulif
newlydiagnos
merck announc
fda approv
tablet oral sodium-
inhibitor
adjunct diet
exercis improv
glycem control
adult type
result
reinforc clinic
benefit ibranc
combin letrozol
announc fda
twice daili xeljanz
mg daili
treatment adult
patient activ
product pipelin develop
progression-fre surviv result phase trial
reinforc clinic benefit ibranc combin letrozol
data present san antonio breast cancer
symposium sabc demonstr combin ibranc plu
letrozol reduc risk diseas progress improv
median one year compar letrozol plu placebo
month ci vs month ci use
initi treatment postmenopaus women estrogen receptor-
updat post-hoc analysi includ median follow-up
three year longest date phase studi
inhibitor overal surviv data yet matur time updat
xeljanz/xeljanz xr tofacitinib decemb announc
fda approv xeljanz mg twice daili xeljanz xr extend releas
mg daili treatment adult patient activ psoriat
arthriti inadequ respons intoler
methotrex disease-modifi antirheumat drug dmard
xeljanz/xeljanz xr first janu kinas jak inhibitor approv
fda moder sever rheumatoid arthriti activ
decemb announc fda extend prescript
drug user fee act pdufa date three month snda xeljanz
review treatment adult patient moder sever
activ ulcer coliti uc demonstr inadequ respons
loss respons intoler corticosteroid azathioprin
mercaptopurin tumor necrosi factor inhibitor therapi
fda determin addit review time necessari due
inform recent submit updat pdufa goal date
decis fda june fda confirm snda
subject gastrointestin drug advisori committe meet
schedul march discuss efficaci safeti data well
benefit-risk consider uc snda
product pipelin develop
decemb announc initi phase
program once-daili inhibitor evalu efficaci
safeti treatment moderate-to-sever atop dermat ad
phase trial random double-blind placebo-control parallel-
group studi evalu patient year older moderate-
to-sever ad trial particip randomli assign receiv mg
daili mg daili placebo
primari endpoint proport patient achiev investig
global assess iga score point improv
proport patient least greater chang baselin
eczema area sever index easi score treatment durat
week durat phase studi
week safeti follow-up period option enter long-term extens
studi week design phase trial base phase
result present congress european academi
dermatolog venereolog septemb
talazoparib decemb announc phase
embraca trial patient germlin inherit
superior patient treat talazoparib investig oral
dualmechan poli ribos polymeras parp inhibitor taken
daili compar patient receiv physician choic standard
median month ci patient treat
talazoparib month ci treat
reduct risk diseas progress addit proport
patient achiev complet partial respons object respons rate
talazoparib group twice control arm
talazoparib vs chemotherapi ci
embraca data present oral present
announc initi
phase program
once-daili
evalu efficaci
safeti
treatment moderate-
announc
compar safeti
efficaci studi pf-
eu met primari
product pipelin develop
potenti biosimilar rituximab januari pfizer
announc phase reflect compar safeti
efficaci studi versu mabthera rituximab-eu met
primari endpoint demonstr equival overal respons rate
firstlin treatment patient low tumor burden follicular
lymphoma develop potenti biosimilar
rituxan rituximab-u /mabthera
one arm phase javelin medley trial pdx-nave pdx-
experienc patient use concurr dose utomilumab avelumab
combin manag safeti profil earli signal
efficaci insuffici support advanc utomilumab avelumab
combin phase trial exploratori analys potenti identifi
patient segment may benefit particular combin continu
detail result trial present futur medic meet
result on-going studi involv utomilumab includ tripl
combin avelumab utomilumab agonist
solid tumor inform next step utomilumab
one arm
medley trial pdx-nave
pdx-experienc
dose utomilumab
avelumab
ertugliflozin
ertugliflozin
xeljanz xr
adjunct diet exercis improv glycem control adult type diabet
mellitu develop collabor merck
adjunct diet exercis improv glycem control adult type diabet
mellitu adequ control regimen contain ertugliflozin
metformin patient alreadi treat ertugliflozin metformin
develop collabor merck
adjunct diet exercis improv glycem control adult type diabet
mellitu treatment ertugliflozin sitagliptin appropri
develop collabor merck
treatment adult patient newly-diagnos chronic phase philadelphia chromosome-
posit ph cml develop collabor avillion
xeljanz mg twice daili xeljanz xr extend releas mg daili
treatment adult patient activ psoriat arthriti inadequ
respons intoler methotrex disease-modifi antirheumat drug
biosimilar remicad infliximab elig indic refer product
adjuv treatment adult patient high risk recurr renal cell carcinoma follow
nephrectomi surgic remov cancer kidney
extended-releas tablet cv once-daili therapi manag neuropath pain
associ diabet peripher neuropathi manag post-herpet
approv japan ibranc combin endocrin therapi treatment
hr inoper recurr breast cancer
approv japan treatment cur unresect merkel cell carcinoma
develop collabor merck kgaa germani
approv eu treatment adult patient metastat merkel cell
carcinoma develop collabor merck kgaa germani
approv eu treatment dult patient relaps refractori bcell
approv eu prophylact vaccin activ immun prevent
invas diseas caus neisseria meningtidi serogroup individu year
age older
approv japan treatment non-smal cell lung cancer
approv eu xeljanz combin methotrex treatment
moder sever activ rheumatoid arthriti adult patient respond
inadequ intoler one disease-modifi antirheumat
drug xeljanz given monotherapi case intoler methotrex
treatment methotrex inappropri
treatment patient alk-posit metastat non-smal cell lung cancer
previous treat one inhibitor
potenti biosimilar filgrastim
potenti biosimilar herceptin trastuzumab
treatment adult patient moder sever activ ulcer coliti
treatment adult patient activ psoriat arthriti
pan-human epiderm growth factor receptor tyrosin kinas inhibitor first-lin treatment
patient advanc non-smal cell lung cancer estim glomerular filtrat rate egfr activ
mutat develop collabor sfj
next gener tyrosin kinas inhibitor treatment patient alk-posit metastat
non-smal cell lung cancer previous treat one inhibitor
prophylact vaccin activ immun prevent clostridium difficil coliti
potenti biosimilar rituxan rituximab
potenti biosimilar avastin bevacizumab
potenti biosimilar humira adalimumab
pan-selectin inhibitor treatment vaso-occlus crisi hospit individu sickl cell
diseas licens
pan-selectin inhibitor treatment vaso-occlus crisi hospit individu sickl cell
diseas licens
long-act hgh-ctp treatment growth hormon defici children develop
collabor opko
long-act hgh-ctp treatment growth hormon defici adult develop
collabor opko
oral parp inhibitor treatment metastat castrat resist prostat cancer
oral parp inhibitor treatment patient germlin breast cancer suscept gene brca
anti-nerv growth factor monoclon antibodi treatment pain develop
collabor lilli
monoclon antibodi inhibit combin inlyta axitinib tyrosin kinas
inhibitor first-lin treatment advanc renal cell carcinoma develop
collabor merck kgaa germani
monoclon antibodi inhibit first-lin treatment stage iiib/iv non-smal cell lung
cancer develop collabor merck kgaa germani
monoclon antibodi inhibit treatment stage iiib/iv non-smal cell lung cancer
progress platinum-contain doublet develop collabor
monoclon antibodi inhibit treatment platinum-resistant/refractori ovarian
cancer develop collabor merck kgaa germani
monoclon antibodi inhibit first-lin treatment ovarian cancer
develop collabor merck kgaa germani
monoclon antibodi inhibit mainten treatment first-lin set
patient urotheli cancer develop collabor merck kgaa germani
monoclon antibodi inhibit mainten treatment advanc metastat
gastric/ gastro-esophag junction cancer develop collabor merck
monoclon antibodi inhibit treatment local advanc squamou cell carcinoma
head neck develop collabor merck kgaa germani
adjuv treatment renal cell carcinoma develop collabor sfj
treatment advanc breast cancer collabor allianc foundat trial llc
treatment high-risk earli breast cancer collabor german breast group
treatment hr earli breast cancer collabor allianc foundat trial llc
treatment non-metastat castrat resist prostat cancer
treatment non-metastat high risk hormone-sensit prostat cancer
treatment metastat hormone-sensit prostat cancer
guidanc conclus
financi guidanc reflect full year contribut consum healthcar
continu expect decis regard strateg altern
consum healthcar made financi guidanc also assum
gener competit lyrica june
expect
franchis continu
strengthen
recent approv
xeljanz psoriat
adjust sale revenu
effect tax rate adjust incom
incom
oper margin
roa
roi roe ttm
basi
respect
gaap ep
revenu estim
adjust dilut ep anticip share repurchas total
finish solid year despit neg revenu
impact due divest hospira infus system also saw
continu growth emerg market oper
innov health strong year driven major product ibranc revenu
grew oper year expect inform
immunolog franchis continu strengthen recent approv
xeljanz psoriat arthriti
essenti health revenu growth continu suffer product strong
oper growth emerg market biosimilar continu eh
segment expect impact
oper margin roa roi roe ttm basi
respect ep
non- reconcili
non- reconcili
non- reconcili
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi compar due decreas cost
revenu growth ttm compar
ep growth ttm compar due increas net margin
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc march
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale pfizer inc march
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale inc march
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item pfizer inc march
outstand equival market properti plant properti plant issuanc prefer issuanc chang pfizer inc march
price-to-earnings volatil around mean due price chang price-to-earnings fallen standard
deviat occas due grow ep declin stock price prove
better year maintain strong price-to-earnings back constant price increas due recent
decreas price price-to-earnings revert back mean level
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form ian frank freda john anthoni alexand loretta dougla institut holdersholdershar report outvalueblackrock vanguard group inc america jp morgan northern trust wellington manag compani geod capit manag price row associ top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut vanguard/windsor ishar fidel select sector spdr fund-health vanguard -valu mf seri trust i-mf valu competit
developmentspf receiv posit chmp opinion hematolog medicin mylotarg bosulif inc announc committe medicin product human use chmp european medicin agenc ema adopt posit opinion recommend two hematolog medicin grant market author european union eu mylotarg gemtuzumab ozogamicin combin daunorubicin cytarabin grant posit opinion treatment patient age year previous untreat de novo acut myeloid leukemia aml except acut promyelocyt leukemia apl bosulif bosutinib grant posit opinion treatment adult newli diagnos chronic phase philadelphia chromosome-posit chronic myelogen leukemia ph cml chmp opinion medicin review separ european commiss ec pfizer announc updat european market author applic sutent sunitinib adult patient high risk recurr renal cell carcinoma inc announc committe medicin product human use chmp european medicin agenc ema recommend expand use sutent sunitinib includ adjuv treatment adult patient high risk recurr renal cell carcinoma rcc follow nephrectomi surgic remov cancer kidney chmp recommend bind taken consider european commiss ec current approv adjuv treatment option avail patient non-metastat rcc high risk recurr european union eu pfizer receiv breakthrough therapi design fda oral inhibitor treatment patient moderate-to-sever atop dermat inc announc once-daili oral janu kinas inhibitor receiv breakthrough therapi design food drug administr fda treatment patient moderate-to-sever atop dermat ad phase program initi decemb first trial atop dermat efficaci safeti jade global develop program eu japan author accept regulatori submiss review third-gener inhibitor lorlatinib inc announc food drug administr fda accept grant prioriti review compani new drug applic lorlatinib lorlatinib investig anaplast lymphoma kinas tyrosin kinas inhibitor tki treatment patient -posit metastat non-smal cell lung cancer nsclc previous treat one tki european medicin agenc japan medic devic agenc also accept market applic use lorlatinib februari inc march
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock
under-perform last
year return
price/sal ratio
lower industri average
gross margin
impress
industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc march
consensu view analyst trend stock
forward price-to-earnings
well
pfe avgfive-year growth forecast usdgrowth high day day day estim comparisonpfeindustri avg avgprice/earn yield inc march
consensu view analyst trend stock
earn growth
estim
revenu growth estim
adjust ep estim
estimatescurr analyst estimatethi estim estimatepast ep growthpeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last daysn/an/an/an/a current surprisescurr growth rate analyst recommend
incom statement
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock came high feb due shrink revenu struggl
bestsel like lipitor celebrex etc
stock given total return last month
stock reach high jan consist increas price
stock given total return last year
stock shown uptrend sinc given total return last year
stock saw heavi movement may high volum reach time high jan
seen consist increas price strong growth net margin pfe blockbust like ibranc
xtandi eliqui etc gain traction world-wide expect growth increas
maintain buy rate target price
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
